Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.

Article Details

Citation
Copy to clipboard

Liu F, Minami H, Silva RR

Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.

Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73.

PubMed ID
19412495 [ View in PubMed
]
Abstract

Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of medications. This paper reviews and summarizes the available research literature on d-MPH regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, and clinical perspectives. d-MPH potentially may offer some advantages in the realms of absorption and duration of action compared with its racemic counterpart. The differences in pharmacokinetics and clinical implications of the immediate-release and extended-release forms of d-MPH are also compared and contrasted.

DrugBank Data that Cites this Article

Drugs